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Abstract 
 
If the field of regenerative medicine is to deliver therapies, rapid 
expansion and delivery over considerable distances to large 
numbers of patients is needed. This will demand efficient 
stabilization and shipment of cell products. However, 
cryopreservation science is poorly understood by life-scientists in 
general and in recent decades only limited progress has been 
made in the technology of preservation and storage of cells. 
Rapid translation of new developments to a broader range of cell 
types will be vital, as will assuring a deeper knowledge of the 
fundamental cell biology relating to successful preservation and 
recovery of cell cultures. This report presents expert consensus 
on these and other issues which need to be addressed for more 
efficient delivery of cell therapies. 
 
Keywords: 
cell therapy • cold-chain • cryostorage • preservation • regenerative medicine • 
stability • vitrification 
 
 
 
 
Background 
The ability to reliably preserve cell preparations for therapy and ship them to healthcare centers 
nationally and internationally presents a key challenge for the delivery of cell therapies. However, 
First draft submitted: 19 April 2017; Accepted for publication: 23 May 2017; Published online: 
TBC 
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the subject of preservation and subsequent shipment, the so-called ‘cold-chain,’ has received 
limited support from funding agencies and key scientific and technical challenges remain which 
present barriers to effective and economic roll-out of new potential cell therapy products. Initiation 
of an expert Steering Group was led jointly by the Cell and Gene Therapy Catapult and the 
National Institute for Biological Standards and Control (NIBSC, a center of the Medicines and 
Healthcare products Regulatory Agency) to develop a strategic framework on key issues in the 
development of our understanding of the technology for sustaining the stability of cell therapy 
products for delivery and storage. Representatives of NIBSC and Cell and Gene Therapy 
Catapult with other experts formed a Steering Group (see Supplementary Appendix 1) to draw 
together, following a focused workshop, a consensus on key challenges and recommendations to 
make progress in assuring successful and stable preservation and shipment of cells for therapy. 
The workshop took place at the NIBSC in May 2015. The remit of the workshop was to garner 
relevant scientific expertise from industry and academia to address current state of the art, 
translational gaps in science and technology and areas that require further research. 
Furthermore, it sought to identify potential ways forward to improve coordination and provision of 
advice to resolve central issues for companies and healthcare services delivering advanced 
therapy products. A meeting report from the workshop with recommendations agreed by 
delegates has since been reviewed by the Steering Group and meeting delegates and is 
presented here providing an expert consensus for use by research funders, regulatory bodies, 
healthcare professionals and researchers. 
 
 
 
 
products please provide a symbol (at first instance only). Can you also please provide the manufacturer name and location 
 
 
The challenges of preservation are influenced by the nature of individual cells such as their size, 
membrane permeability, morphology, ultrastructural complexity and composition of subcellular 
organelles, as well as the cell density and composition of the preservation medium (see reviews 
in [1-3]). A fundamental underlying factor to cryopreservation in any format is water stress (due to 
osmotic effects and ice formation), which the group believed to be still poorly understood, and 
requires further basic research 
These defining characteristics are complicated by the presence of multiple cell types or their 
combination with noncellular components, such as extracellular matrix or artificial scaffolds in 
certain therapies. While it was clear that a one-size-fits-all approach to preservation of cellular 
(city/state, country). 
Session 1: Categories of cell systems[Query-Q7: Kelvin Adu-Darko(PE) to All(AU)]For all branded 
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function  across  such  a  diverse  spectrum  of  cell  therapy  products  was  impracticable,  a 
rationalized approach is needed as the empirically derived processes would not be the same in 
different systems. While no cell system is completely homogenous, it was concluded that it would 
be helpful to develop a set of simple cell-based model systems to understand the challenges of 
preserving key types of cell therapies (see Box 1 for Recommendation 1) [Query-Q8: Vikas Sharda(CE) 
to All(AU)] Please check and confirm that any figures/tables/boxes that appear in the article have been redrawn correctly, and i 
not, please describe any corrections that need to be made.  Such cell-based models systems could enable the 
development of new approaches for preservation and storage at ultra-low or otherwise controlled 
conditions. It was envisaged that these systems should include a uniform cell suspension type 
(such as blood-derived T cells), undifferentiated human pluripotent stem cells, cell aggregates 
(e.g.,  hepatocytes,  neurons)  and  a  combination  product  such  as  mixture  of  fibroblasts  and 
keratinocytes. An overall structure for these model systems should also take into account the 
processing involved, scale of processing and in particular the time between preparation and 
delivery to the patient, as illustrated in Figure 1. It will be important to understand the different 
potential responses of cells in vivo versus in vitro. Furthermore, it would be important in these 
studies, to minimize the influence of operator variability and the group concluded that automated 
processing  was  now  sufficiently  well  developed  to  provide  processing  solutions  that  could 
eliminate this source of variability. 
 
Box 1. Recommendation 1. 
 
 
A coordinated program of research into cryopreservation methods using relevant exemplars 
from cell therapy. This would include: 
 
• Development of a set of simple model systems that could be used to understand the 
challenges of preserving key types of cell therapies 
• A large study investigating different media and matrices for preservation of model 
systems engaging expertise in – omics analysis 
• Further R&D funding for investigation of cell freeze-drying and cell permeabilization 
methods that could provide game-changing discoveries 
• Investigation  of  alternative  cryoprotectants  to  DMSO  which  engages  chemistry 
expertise to select and screen appropriate compounds and [Query-Q9: Kelvin Adu-Darko(PE) 
to All(AU)] Can the "and" at the end of preceeding sentence be removed please. Please can you also define 
 DMSO. 
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• Investigation of a combinatorial approach combining cryopreservation with 
hypothermic storage 
 
 
 
 
 
 
(AU)] Please could you let me know if you would like your figures printed in colour? The cost of colour printing is UK£155 
 
Figure 1. Potential models systems to assess new preservation strategies[.Query-Q10: Kelvin Adu-D 
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is c o u o a rt ic e w t h t w o o m o g u r e s 
 
 
 
Donor cell harvest to recipient time: 
a) Hours: risk assessment similar to transplantation and bioprocessing should assure little or no chang 
preparation. 
b) Days: key additional hazard is expansion of microbial, contamination requiring new rapid methods 
viability and efficacy requiring careful characterization. 
c) Preservation steps for seed stock enable long-term storage of seed stocks, intermediate cell preparati 
product thus permitting careful characterization and safety testing to provide greater confidence in efficac 
 
 
 
 
 
Session 2: Fundamentals of preservation & recovery 
Successful preservation is dependent on a number of pre-preservation strategies in addition to 
those already mentioned above. The culture methodology may influence cell morphology and can 
be adjusted (typically into the logarithmic phase of growth where cells often display a high 
nuclear/cytoplasmic volume ratio). Cellular permeability may change with temperature which may 
need to be taken into account for the development of cooling profiles. Water content is clearly a 
critical issue in cryopreservation of cell preparations but it was recognized that all ultra-low 
temperature preservation methods ultimately invoked vitrification even if only as a final event 
during cooling. This has implications for method development and storage conditions [4]. 
Vitrification by rapid freezing has proven useful in several systems, but suffers from the difficulty 
in maintaining the integrity of cell–matrix structures, amenability of thawing procedures for routine 
clinical use [5] and scalability. The group noted that the benefits of vitrification methods had yet to 
be realized but may be enabled by the development of automated freezing and thawing systems 
[6-8]. 
The group considered that one of the major issues, which had held back the development of 
new and more effective preservation methods, was the common practice in published literature to 
report measurements of viability immediately post thaw. In the absence of contextualization of the 
preparation and condition of cells prior to preservation or indeed a suitable timeframe and a short 
time after recovery (when consequences of the preservation process on viability and cellular 
function were clearer), this was a confounding issue. 
It was recognized that some cellular systems that appear to have similar characteristics may 
respond very differently to preservation methods. This observation may be due to differences in 
their prior exposure to environmental conditions, direct or indirect activity of other cells to which 
they have been exposed and other bioprocessing factors. Approaches to preservation, shipment 
[Query-Q11: Kelvin Adu-Darko(PE) to All(AU)]Please can we delete the box at the bottom of the figure as the information is a 
the figure legend. 
d nt f  r l  s   i r re fi 
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and recovery would therefore need to take such factors into account and provide coherent 
records of results (see Box 2 for Recommendation 2). 
 
Box 2. Recommendation 2. 
 
 
A coordinated research program into the fundamental elements of cell biology associated 
with stability and successful preservation. This should include: 
 
• The development and application of more appropriate and quantified measurement of 
viability and survival specified for particular applications, including epigenetic, 
metabolomics and transcriptomic profiling 
• Careful comparative studies to elucidate the benefits of well controlled  hypoxic 
culture conditions for therapies 
 
Delivery of cell therapy products to large numbers of patients is unlikely to be achieved using 
a continuous culture manufacturing process and will require the ability to produce and preserve 
large batches or necessitate multiple site manufacturing. Closely controlled workflows and culture 
conditions should increase consistency in the cellular preparations and the ability to recover 
consistently viable and functional cells. However, it was concluded that the current reality was 
that it may be necessary to accept substantial losses of cells and accommodate reasonable 
recovery of adequate cell populations for clinical use. However, as for any preservation process, 
it would be necessary to demonstrate consistency between the pre and post preservation cells to 
give confidence that potency/efficacy of the cell product for its intended purpose was sustained. 
The preservation and recovery of cell preparations clearly represents a dynamic process of 
changing cell condition and snap-shot quality control of cell recovery may be significantly 
misleading, particularly for cell analysis immediately post thaw. It was, therefore, concluded that 
at least when developing new or modified preservation methods, recovery of cell preparations 
needed to be monitored over a period of time post thawing, to create a profile of cell recovery and 
replication until full functionality was attained. 
 
Session 3: Characterization of cellular preparations 
Traditionally, a pragmatic approach has been adapted to the level of characterization for cell 
therapy preparations, as to date, most uses of cell therapy have been in urgent treatment of life- 
threatening conditions such as leukemia. However, given the broad range of applications of cell 
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therapy now under development, the risk/benefit balance may be very different and a greater 
ability to predict clinical response may be required or mandated by regulators. 
The type and level of characterization necessary to demonstrate sustained viability and 
functionality of the final cell therapy products will depend on the cell type/s involved but should 
primarily address the demands of their application. The group concluded that in general, for final 
cell preparations for therapy, it will be important to consider not only markers of features that are 
expected for therapeutic function, but also markers that are contraindications for clinical use of 
the cells. The group considered that this area of discussion needed to be explored further through 
a workshop on cell viability and function (see Box 1 for Recommendation 1). 
In the case of pluripotent stem cells the group concluded that current cellular markers may not 
be sufficient as in some cases their function in stem cells has yet to be identified. However, as 
part of the profile of expression, the cellular markers are important identity markers of the culture 
type. Nevertheless, functional assays are needed to complement currently used markers of self- 
renewal (e.g, Nanog, Sox2, Oct-4) which are necessary but not sufficient to demonstrate the 
pluripotent potential of these cells with timely and realistic assays. 
Appropriate analytical methods for capturing the properties of cell preparations are often 
performed at key quality control points in bioprocessing. However, the group identified that these 
represent snapshots of a dynamic and often evolving cellular system. Mapping this process with 
in-process testing may well be crucial to successful preservation and recovery of a functional cell 
therapy product. Examples of clinical and scientific evaluation of primary tissues and cells have 
been developed in fields such as IVF where cells must be used within a few hours. [Query-Q12: Kelvin 
 
 
The group agreed that reference cell preparations may be useful but, in general, for cell 
therapies where the products are extremely diverse, these may need to be product specific. 
Nevertheless, the group also concluded that it may be helpful to develop reference materials for 
the analytical methods used to characterize cell preparations. 
It was recognized that in the development of biotechnology, systems biology studies of the 
genome and transcriptome had been an important factor in the development of cell culture 
systems to assess the impact of different culture conditions [9], but relatively few studies had 
been performed on the impact of preservation [10,11]. The group agreed that further discussion 
on the application of such deep systems analysis for cell preparations for cell therapy could assist 
in  the  assessment  of  preservation  methods.  Furthermore,  in-depth  studies  of  different 
Adu-Darko(PE) to All(AU)]Please can you define IVF 
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combinations of different culture media and matrices using high-throughput approaches are likely 
to identify improved preservation and stability of models systems as had been developed for 
gametes [12,13] (see Box 2 for Recommendation 2). 
The potentially valuable contribution of low oxygen culture conditions for cells in culture was 
recognized and recent publications that have demonstrated this for clinically relevant cells (e.g., 
[14-17]. However, specific benefits for preservation and stability of cell preparations had yet to be 
demonstrated and required further research (see Box 1 for Recommendation 1). In conclusion, 
future studies of stability for cell therapy systems would need to consider culture medium, 
atmosphere and surface matrix in the context of their impact on cell biology. 
The group concluded that experience with a broader range of assays that measured or 
correlated with cell function, should be developed for the evaluation of preservation techniques 
(see Table 1) (see Box 1 for Recommendation 1) and that studies of model systems (Figure 1) 
were required. 
 
Table 1. Levels of analysis for evaluation of viability and function for cell therapies. 
Feature of cell biology Methods and exemplar studies 
Membrane integrity/function (and lipidomics), Membrane associated enzymes (fluorescein diacetate 
test for membrane esterases), membrane degradation 
test such as malondialdehyde assay, lipidomics 
 
Structure and function of subcellular 
organelles and [Query-Q13: Kelvin Adu-Darko(PE) 
to All(AU)] Can the word "and" be removed from the 
end of this sentence please. 
Mitochondria, nucleus, endoplasmic reticulum, protein 
folding 
 
Biochemical pathways and key molecular 
complexes 
Proteasome, epigenome, transcriptome and metabolome 
 
Metabolic flux Mitochondrial functions 
Adherence mechanisms Integrin expression 
Single cell analysis Studies of subpopulation analysis using live cell imaging, 
MALDI, Raman spectroscopy, single cell analysis (e.g., 
sequencing, expression profiling) electrophysiology, 
cryomicroscopy among others. 
Image analysis and morpholomics New approaches to applying metrics to cell morphology 
such as neurite outgrowth [Query-Q14: Vikas Sharda(CE) to All 
(AU)] Please check and confirm that the preceding sentence has 
been edited correctly. 
Cell functionality and response Real-time measurement of calcium imaging 
Response to reference compounds including TNF-α and 
toxicants 
http://powerxeditor.aptaracorp.com/fsg/PXEEditor/EditorInit.aspx?configPath=D:\PX...  07/06/2017 
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Session 4: The notion of viability 
It was agreed that there was very little in the literature on thawing of cryopreserved material and 
there had been modest progress on methodologies for reliable and reproducible thawing. 
However, the method of thawing can be critical to successful recovery. Various thawing 
temperatures had been used between 32 and 40°C and it was agreed that two key factors in 
determining the veracity of such data were full and accurate description of the thawing method 
and records of the actual temperature profile within individual vials. The group noted that there 
was now equipment available on the market (e.g., ThawSTAR, VIAThaw) which could potentially 
improve reliability and reproducibility of thawing and recommended that this was an area where 
rapid improvements could be made (see Box 3 for Recommendation 3) and some progress had 
already been made in the application of microwave induced thawing [18]. 
 
Box 3. Recommendation 3. 
 
 
The group identified areas where translation of current knowledge and expertise could lead 
to early improvements in current preservation and shipment technology and these included: 
 
• Investigation of ‘hibernation media’ which had proved successful with some cell types 
and their assessment for broader application with cell therapy preparations and 
• Use of newly available thawing equipment to improve reliability of thawing and viable 
cell yield 
 
Understanding of delayed onset cell death in cell preparations post cryopreservation could 
give valuable information to help improve efficiency and efficacy of cell therapies [19,20]. 
Furthermore, the levels of nonviable cells and cell debris may be important in assessing whether 
a product is fit for use as these may cause the product to cause inflammation or other 
undesirable responses. Cell death itself is also a complex process that may involve one or 
multiple different programmed and/or nonprogrammed biochemical processes some of which 
may be initiated as cell survival processes, such as autophagocytosis. The group agreed that 
there may be biological consequences of evading cell death, such as genetic change and cell 
transformation, which could impact on cell function and product safety. Thus, it was clear that 
viability assessments should go beyond simple enumeration of cell numbers to facilitate a greater 
understanding of the cell system in question and there was a need for awareness that the same 
Rate of cell death Assessment of rates of replication and death 
http://powerxeditor.aptaracorp.com/fsg/PXEEditor/EditorInit.aspx?configPath=D:\PX...  07/06/2017 
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cell  preparation  can  yield  different  results  with  different  test  methods  [21-23].  The  group 
concluded that test  methods for viability should provide  data on both  viable and nonviable 
populations, using a test regime based on a fundamental understanding of the cell preparations 
in question. In addition, there was a need for more sophisticated approaches to assess cell 
numbers. The group concluded that a future activity stimulated by the workshop steering group 
should be to address the needs for evaluation of the quality of in-put or ‘feedstock’ cells which 
should incorporate mechanisms of activation of cell death and identification of appropriate 
surrogate assays of functionality (see Box 4 for Recommendation 4). 
 
Box 4.     Recommendation 4. 
 
 
The group proposed that further interaction between academic, commercial and regulatory 
stakeholders should be promoted in meetings and workshops specifically in the following 
areas: 
 
• Coordination of current horizon-scanning activities to spread knowledge of new 
potential methodologies. This should be linked to a ‘test bed’ function to provide rapid 
evaluation and development of generic benefits through qualification of new assays 
and control materials 
• Assessment of the requirements for long-term storage systems to assure low- 
maintenance, well-documented, secure and contamination-free systems and the 
development of accelerated ageing studies which could be useful for cell therapies 
Workshop activity should include manufacturers, cell biologists, microbiologists, 
cryobiologists and clinicians 
• Address the needs for evaluation of the quality of ‘feedstock’ cells or starting cultures, 
incorporating consideration of mechanisms of activation of cell death and 
identification of appropriate assays of viability and function 
• Evaluation of the value that nonlinear cooling rates might hold for improvement in 
preservation technology 
• The impact of ambient temperature storage on cell biology 
• Cross agency coordination should be promoted including the KTN manufacturing 
activity on transplants [Query-Q15: Vikas Sharda(CE) to All(AU)]Please define the following term: KTN. 
http://powerxeditor.aptaracorp.com/fsg/PXEEditor/EditorInit.aspx?configPath=D:\PX...  07/06/2017 
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While  it  was  broadly  recognized  that  cellular  stress  is  a  significant  issue  to  address  in 
successful preservation, this is a complex aspect of cell biology due to the heterogeneity 
associated with the levels of synchronicity, phenotypes of cell populations and the physical 
heterogeneity of the culture systems. This heterogeneity could include shear force, oxygen, 
carbon dioxide etc. Furthermore, it was acknowledged that priming a cell system (e.g., induction 
of enzyme protective against reactive oxygen species, induction of heat shock protein 
expression) may influence successful survival of preservation processes, but relatively little is 
published in this area and current publications typically deal with preservation of gametes with 
specialized biological characteristics [24-28] (see Box 2 for Recommendation 2). 
 
Session 5: Formulation of & delivery of cell therapy products 
In order to facilitate a fundamental re-evaluation of approaches to preservation and stability of cell 
therapy products it will be important to understand the different formulations in which cells will be 
delivered to the patient and the cold-chain supply. The transfer of frozen or growth-inhibited cells 
from central storage to local storage, followed by recovery, formulation and injection to the patient 
must be considered as a whole process at an early stage in development of the product to 
generate an effective and efficient delivery chain to enable critical road-blocks to be managed 
proactively. 
 
Session 6: New technical opportunities 
Preservation technologies 
Significant effort has been put into freeze-drying cells, however, to date, success has been very 
limited [29,30]. The group concluded that this is clearly an area where further research could 
have a huge impact in the field of regenerative medicine and beyond. Another important area for 
development was the identification of new cryoprotective agents. Work was already being carried 
out with compounds used in nature such as trehalose, which combined with new cell 
permeabilization approaches (e.g., bacterial toxins, artificial membrane pores,  micelles)  [30] 
could provide new game-changing preservation methodologies (see Box 1 for Recommendation 
1). Plant and algal cell preservation experience (e.g., Scottish Association for Marine Sciences) 
and expertise in chemical excipients which modify in vivo structures may also be valuable and 
are being developed commercially by Croda [31]. 
http://powerxeditor.aptaracorp.com/fsg/PXEEditor/EditorInit.aspx?configPath=D:\PX...  07/06/2017 
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DMSO? 
 
 
Technologies for analysis of cryopreservation systems at ultra-low temperatures, depend on 
physics and materials sciences and include differential scanning calorimetry and neutron 
scattering and such technologies may have application in the design and evaluation of new 
methodologies for model systems (Figure 1). The group felt that this and other areas discussed at 
the workshop would benefit significantly from coordination of existing horizon-scanning activities 
to spread knowledge of new potential methodologies. Further, this should be linked to a ‘test bed’ 
function to provide rapid evaluation and development of generic benefits through qualification of 
new assays and development of control materials (see Box 4 for Recommendation 4).  An 
example would be high-throughput evaluation of a range of cryoprotectants or protocols (see [13] 
and below) which could be facilitated by combinatorial experimental tools. Such tools might 
include the bead technology developed by Plasticell Ltd (UK) for the study of stem cell 
differentiation, which apparently can be used with alginate encapsulated cells (personal 
communication Dr Y Chen, Plasticell). 
Cryoprotectants 
Various cryoprotectant products are on the market but delegates agreed that these were largely 
based on well-proven methods and reagents. The workshop members felt that there could be real 
benefits for cell therapies through exploring new approaches and use of novel excipients (e.g., 
Crodar) may also be helpful.  [Query-Q16: Kelvin Adu-Darko(PE) to All(AU)]Please can you check whether the word 
intended in the preceeding sentence is "Croda" rather than "Crodar"G. eneration of new cryoprotective agents 
 
molecules is also an area of active research for some applications [32,33]. Large libraries of such 
molecules can be synthesized, however, the rate limiting step is testing them with cells under 
conditions representative of standard cryopreservation. 
Delegates  concurred  that  there  was  a  general  perception  in  the  field  that  DMSO,  the 
cryoprotectant most commonly used in preservation of cells for clinical use, was undesirable 
given the broad-ranging and potentially toxic impact on cell biology. It had been proposed that in 
the long term DMSO should be replaced. [Query-Q17: Kelvin Adu-Darko(PE) to All(AU)]Please can you define 
The group felt that whilst DMSO could be deleterious under certain circumstances [34], 
this perception was, to date, causing some companies to consider suboptimal systems for 
cryoprotection. It was agreed that a published review of the reality of DMSO toxicity would be 
extremely valuable (see Box 5 for Recommendation 5). This should include the long history of 
safe use (notably in bone marrow transfusion for more than 40 years), documented adverse 
events, effectiveness of enhanced removal methods, future need for new alternatives and a way 
http://powerxeditor.aptaracorp.com/fsg/PXEEditor/EditorInit.aspx?configPath=D:\PX...  07/06/2017 
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forward to identify and select these. However, the group also agreed on the need to explore 
alternatives to DMSO through the engagement of chemists, to select and screen appropriate 
compounds (see Box 1 for Recommendation 1). 
 
Box 5. Recommendation 5. 
 
 
• Finally, the group identified that a published review addressing the reality of DMSO 
toxicity would be extremely valuable. This should include history of use, documented 
adverse events, effectiveness of enhanced removal methods, future need for new 
alternatives and a way forward to identify and select these 
 
Ice-nucleation 
The group unanimously agreed that ice nucleation was a critical but largely  uncontrollable 
variable in small sample volumes. This could result in variation in cryopreservation which may be 
observed between individual cryovials filled from the same batch of cell suspension (personal 
communication, Dr J Morris, Asymptote Ltd. UK). 
Chemical inducers of nucleation had been developed for addition to preservation medium and 
some had achieved regulatory acceptance for clinical use. Other technologies included bubbling 
of nitrogen vapor through the medium which required clinical grade liquid nitrogen. Procedures to 
assess and control the quality of liquid nitrogen under GMP where some manufacturers consider 
it an excipient were required. However, a formal standard for clinical grade liquid nitrogen has yet 
to be established, although requirements for storage system cryogens are covered in regulatory 
guidance such as ICH Q8 [35]. Ultra-sonic treatments have also been trialed, but these depend 
upon inducing cavitation which causes serious local heating and shock events [36]. 
Cooling rates 
The use of linear cooling rates is widespread in current technology but it was agreed that few 
systems achieve truly linear cooling and nonlinear rates or multiramp profiles [37] are known to 
provide significant improvements in cell preservation [38]. Investigation of nonlinear rates could 
provide some ‘quick wins’ in the development of new preservation methods. The group proposed 
that nonlinear cooling rates should be an area for further discussion and coordination. (see Box 4 
for Recommendation 4). Furthermore, in order to avoid misinterpretation of cooling rate data, it is 
important to be sure that the actual cooling rate experienced by the cell preparation is measured 
during cooling experiments and not just the surrounding environment. New ultrasound-based 
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technologies are currently being used as novel biosensors in cell culture systems (such as those 
developed by OJ Bio [39]) [Query-Q18: Kelvin Adu-Darko(PE) to All(AU)]Please can you provide a working url for this 
reference . These systems could also be considered to monitor cooling rate but may not offer bio- 
survival data as the technique is dependent on antibody interaction. 
Cell & tissue encapsulation 
Encapsulation has been used in the preservation a variety of organisms and tissues including 
bacteria, fungi, plant meristems and disaggregated liver and pancreatic cells [40-43]. The group 
felt that the potential of this technology, in assisting the stabilization of mammalian cell 
membranes and avoidance of ice damage, could offer significant advancements in 
cryopreservation and storage stability. Use of either barium or calcium ion-induced polymerization 
of alginate was now used widely with mammalian cells which could also be recovered with good 
viability from alginate capsules following controlled depolymerization. Published examples include 
fibroblasts [44], disaggregated liver [43], pancreatic islets [45,46] and differentiated pluripotent 
stem cells [47]. Furthermore, novel developments for this approach include syringe preservation. 
 
Session 6: Storage systems 
There was unanimous agreement by delegates that much of the equipment for cooling and 
storage at ultralow temperatures had not progressed significantly for decades. It was noted that 
further discussion with manufacturers could yield some progress toward modernization and 
improvement of their suitability for use with the new generation of cell therapeutics (see Box 4 for 
Recommendation 4). In contrast, data storage and inventory control were areas where real 
advances had been made. In particular, it was now possible using RFID technology (such as 
being developed by CryoGatt Ltd UK [48]) to check inventories of stored material. In addition, the 
technology had been developed by groups such as IBMT (Fraunhofer Institute, Germany [49]) 
which provided an ultra-cold resistant chip within individual cryovials which store the temperature 
history and detailed cell banking data for that vial. The group concluded that there were now 
automated access systems (e.g., see [49]) which may provide cost-effective storage and 
noninvasive temperature monitoring solutions for cell therapies. 
 
Session 7: Thawing methods 
As already detailed, new improved methodologies for thawing are required and new approaches 
such  as  ultrasound  induced  melting  and  rapid  thawing  using  electromagnetic  excitation  of 
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nanoparticles  may  provide  suitable  solutions  for  certain  applications  and  are  available 
commercially (e.g., Nano Biosils [50], oi-li-tech nanomaterials [51]). Clearly, the mechanism of 
heating should be carefully investigated for adverse effects on the cells and compounds to which 
therapeutic cells are exposed to achieve clinical and regulatory acceptability and approval. 
However, given that modern vial materials usually restrict heat transfer rates, new methods for 
rapid and reproducible thawing are urgently needed that provide efficient and rapid thawing to 
assure adequate cell survival. 
 
Session 8: Storage & shipment of cells 
Cryoshipments 
Shipment of cryopreserved material will continue to add significant cost to the delivery of cell 
therapies based on current methods. Key issues for shipment of cryopreserved cells which would 
benefit from new developments include: 
 
• The requirement for stable ultra-low temperatures to be maintained for days or weeks, 
under, at times, hostile environmental conditions, without interventions such as recharging 
cryogens by shipping agents. 
• Sealing and containment systems that prevent exposure to environmental contamination. 
• Robust labeling conventions, standardized product nomenclatures (such as the new WHO 
INN standard nomenclature for cell therapy products [52]) and labeling materials resistant 
to ultra-low temperatures and of suitable size to fit on cryovials. 
 
It was noted that there were a number of existing coordinating activities that could provide useful 
support and in particular the Knowledge Transfer Network manufacturing activity on 
transplantation should be contacted [53] (see Box 4 for Recommendation 4). 
Transport of live cultures 
The clinical application of cell-based therapeutics has come to the fore, with the number of novel 
clinical trials demonstrating a dramatic increase in the last decade, accompanied by an 
emergence of approved cell therapy products to the market. A major bottleneck for cell 
therapeutics is that the products comprise live cells with short shelf lives. This is a significant 
challenge for successful completion of quality, safety and efficacy testing, and subsequent 
distribution from the donor or bank, to sites of processing and back to the clinic. Although 
cryopreservation is likely to be required for the long-term storage of cells, some cellular systems 
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are not amendable to the application of current methods (discussed above). Thus, the transport 
of cells in their liquid viable state may be necessary or indeed advantageous [54]. In a recent 
assessment by experts in the field, it was considered critical that improved preservation and 
transport enabling technologies be developed in order to eliminate GMP-regulated process steps 
of preservation removal and cell thawing [55]. This might fit with centralized production facilities 
for cell therapies, with cryobanking for stock control, followed by thawing and distribution of live 
cell products. 
Hypothermic storage of cells (over a range of 0–34°C degrees), has been recorded to avoid 
many of the issues associated with cryopreservation. However, delegates still shared concerns 
over limited time-windows where difficulty in timing the transfer of cells to the clinic due to a 
restricted, inflexible shelf-life could result in a high level of wastage of materials [56]. Extending 
the shelf-life of hypothermically-stored cellular products, without significant loss of viability and 
therapeutic potency, could therefore, offer a number of benefits at multiple stages during 
bioprocessing for both autologous and allogeneic therapies. Extended shelf life would extend the 
period for completion of quality assurance, sterility testing, characterization and efficacy testing. It 
would also reduce the risk of wastage due to inadequate continuity between sites of processing 
and disrupted patient scheduling at the clinic. Additionally, where a course of therapy requires 
application of repeat tissue samples or cell dosing, multiple products could be stored at the clinic 
obviating the requirement for multiple shipments. 
Current work at the University of Newcastle had developed alginate encapsulation of cells for 
the hypothermic storage of a range of cell types [57]. For some products a combination of cryo- 
storage and hypothermic storage to obtain the benefits of long-term cryostorage with the ease of 
handling and reduced shipping costs of hypothermic storage of the thawed cells could be 
advantageous. The group concluded that this approach should be considered as an area with 
significant potential benefit enhanced by collaboration between academics and manufacturers 
(see Box 1 for Recommendation 1). Ongoing work at Newcastle was exploring the biological 
mechanism behind this alginate encapsulation hypothermic storage approach using adipose 
derived stem cells (stromal fraction) and image analysis at IBMT (see above) has provided useful 
direct cryomicroscopy evaluation of the cryopreservation process in individual beads. 
Live cultures can be shipped with success and the use of so-called ‘hibernation media’ have 
been used for many years for therapeutic cells. It was noted that HypoThermasol FRS (BioLife 
Solutions) [Query-Q19: Kelvin Adu-Darko(PE) to All(AU)]Please can you provide a city or state and country location for 
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with a published composition including DMSO, has been qualified for shipment at 
2–8°C and is capable of sustaining viability of cell preparations for up to 30days. However, its 
application in other cells-types had not yet been investigated and the group felt this could be a 
valuable  and  straightforward  piece  of  work  that  could  be  coordinated  between  interested 
researchers and the manufacturer (see Box 3 for Recommendation 3). Shipment at higher 
temperatures had also been qualified by Organogenesis who had successfully sustained cell 
viability following transport at 25°C for 5 days and 20°C for 15 days. Other approaches to 
metabolic regulation by controlling may facilitate liquid ambient (around 20°C) temperature which 
does not appear to necessarily impact on cell viability and function [58-60]. The Group felt this 
deserved further expert discussion to identify the key metabolic changes from 37°C down to 20°C 
(see Box 4 for Recommendation 4). The group also agreed that perfluorocarbons for oxygen 
support [61] and hydrogels also presented potentially valuable media to explore for cell shipment. 
In common with the all-too-many publications of ‘successful’ cryo-preservation methods, 
publications on hypothermic storage methods also lacked standardization in terms of validation of 
success. The value of such publications to industry and healthcare, as well as in taking the 
science forward, was currently limited. The group concluded that this situation could be 
significantly improved if a set of ‘measurands’ could be agreed that included some quantifiable 
assessment of functionality relevant to the therapeutic purpose of the product. One such model of 
potential value has been developed, which establishes a single value combining percentage 
viable cell release (not simply percentage cell viability) with mitochondrial metabolic activity post- 
cryopreservation and release [62]. 
Long-term storage issues 
A range of events were known to cause loss of viability in preserved materials including 
environmental radiation, poor handling practice resulting in partial thawing of material, 
temperature cycling above the glass transition temperature (leading to crystal growth and cell 
death) and physical shock of vitrified systems causing loss of viability. It is important to 
understand the factors that determine the critical storage temperature. Studies had shown that 
human cells can be stored for more than 30 years and that other biological cellular materials for 
more than 50 years (for a review see [63]). Stability of viability in cryopreserved liquid cell 
suspensions was known to be very limited at temperatures around -80°C and was totally 
unsuitable for vitrified material, where the glass transition temperature was much lower, in other 
words,  often  below  -150°C.  The  manufacturing  requirements  for  storage  of  cryopreserved 
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materials may vary depending on whether the material is stored short term (e.g., awaiting quality 
control, shipment) or if the material is in long-term storage such as a manufacturer’s master cell 
bank which may be used over several decades. Approaches, to simulate long-term storage using 
‘accelerated aging’ techniques, have been developed for seeds and protein preparations [64,65] 
but new approaches may be needed for preserved cells, possibly focusing changes of phase and 
micro-environment. It was proposed that such approaches should be considered for adaptation 
for cell therapies. It is clear that long-term storage vessels need to be redesigned to assure low 
maintenance, well-documented, secure and contamination free systems – this could be the 
subject of a further workshop sessions with manufacturers, cell biologists, microbiologists, 
cryobiologists and clinicians (see Box 4 for Recommendation 4). 
 
Conclusion 
It was strongly argued that the broadly held perception that the challenges of cryopreservation 
were resolved and did not need further development was mistaken and had been a significant 
reason for the lack of progress in this area. Current press and public interest, in light of recent 
court rulings on cryonics, only emphasize the need for measured scientific and technological 
approaches. These along with the application of more relevant characterization of cell biological 
functions, could lead to significant improvements in yield of viable and functional cells and greater 
efficiency in cell therapy production chains. It was concluded that these benefits would justify the 
R&D investments recommended by the group and furthermore could reduce the cost of future 
regenerative  medicine  products [Query-Q20:  Vikas  Sharda(CE)  to  All(AU)]Please  check  and  confirm  that  the 
preceding sentence has been edited correctly.  The recommendations agreed by the workshop delegates 
are summarized below. 
 
Future perspective 
Once new cell therapies show efficacy there will be an immediate demand for efficient 
international delivery of cell therapies which will be dependent upon the ability to store and ship 
cell therapy products stably and reliably. New developments to support this will come from 
translation of learning from one cell product to another and in considering new solutions to 
storage and recovery equipment. Investigation and evaluation of new cryoprotectants in different 
cell systems will also be important in the coming years and research funders should be 
encouraged to support new coordinated research programs to facilitate early evaluation and 
translation in industry. 
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Executive summary 
 
• This report summarizes consensus among a specially selected expert group on key 
issues in assuring stable storage and shipment of cell therapy products. 
• The discussion covered a broad range of fundamental cell biology and preservation 
issues which need to be addressed to establish and qualify preservation and storage 
methods suitable for cell-based medicines. 
• In particular, the group discussed potential model cellular systems for preservation 
development and certain neglected but vital aspects of fundamental cell biology and 
cryopreservation. 
• They also addressed the need for effective characterization and viability assessment of 
preserved cells and approaches to formulation of preserved cell-based medicines. 
• Finally, the group also considered new technical opportunities for cryopreservation, 
storage, shipment and cell thawing. 
 
Workshop recommendations 
 
• A number of areas were considered in need of fundamental scientific development and 
are summarized in Recommendations 1 and 2. Other recommendations addressed 
potential early benefits that could be obtained from dissemination of current techniques 
and new instruments (Recommendation 3) and opportunities for advanced 
understanding of the issues through key coordination activities (Recommendation 4 and 
5). 
 
Conclusion 
 
• The group concluded that there were clear and significant benefits to be gained from 
implementation of these recommendations for effective safe and efficient roll-out of cell 
therapies. 
• The issues of cell stability and preservation need to be addressed early in product 
development and are of particular importance to underpin the current dramatic 
expansion of cell-based medicines such as immunotherapies including CART cells 
[Query-Q21: Vikas Sharda(CE) to All(AU)]Please define the following term: CART.. 
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